Over-the-counter products sit in an awkward gap. They are regulated as drugs, but they compete at the shelf like consumer goods, which means an OTC carton has to satisfy a federal labeling scheme and still sell the product.
OTC secondary packaging must carry a compliant Drug Facts label in the prescribed format and order, display the required identity, net quantity, and responsible-party statements, provide tamper evidence where the product is accessible to the public at retail, meet child-resistant requirements for certain substances, and provide a coding area for lot and expiration dating.
This guide covers what each of those means for the carton, and where compliance and shelf performance collide. It is written for beauty and personal care teams in particular, because the most common way a brand ends up with OTC obligations is not by setting out to make a drug. It is by adding an SPF claim to a moisturizer.
What Counts as an OTC Product
OTC stands for over-the-counter: a drug sold directly to consumers without a prescription. In packaging terms that means a product regulated as a drug by FDA, but bought off a shelf like a cosmetic or a grocery item.
Everyday examples include pain relievers, antacids, allergy tablets, and cough and cold remedies, but also sunscreen, acne treatments, anti-dandruff shampoo, antiperspirants, and fluoride toothpaste. That second group matters most here, because they are the products a beauty team often assumes are cosmetics.
Two routes put a product in this category.
Monograph products conform to an established set of conditions for a therapeutic class: permitted actives, concentrations, indications, and labeling. Meet the monograph and the product can generally be marketed without product-specific FDA approval. The CARES Act, signed March 27, 2020, added section 505G to the Federal Food, Drug, and Cosmetic Act, replacing rulemaking with an administrative order process for revising them.
NDA and ANDA OTC products are approved individually, usually because they fall outside a monograph or switched from prescription status.
The Cosmetic-Drug Crossover
This is where beauty and personal care brands are most often blindsided. A product can be a cosmetic and a drug at the same time, and when it is, the drug requirements apply in full.
The packaging consequence arrives mid-project and is rarely welcome: a carton designed as beauty packaging now has to carry a Drug Facts panel at prescribed type sizes, on a structure whose dimensions were set by the primary container and the design. Note that antiperspirants are drugs while deodorants are cosmetics, which catches teams out on what looks like one product line. Establish regulatory status before the dieline is drawn, not after.
What Packaging Requirements Apply to OTC Products?
Drug Facts Label
21 CFR 201.66 prescribes the panel in detail, which is the point: it standardizes Drug Facts so consumers read every OTC product the same way.
Required content, in this order: Drug Facts title, Active ingredients, Purpose, Uses, Warnings, Directions, Other information, Inactive ingredients, and optionally Questions with a contact.
Format rules that constrain design:
- Title set larger than the largest type size used elsewhere in the panel.
- Headings the larger of 8-point or 2 points above body text; subheadings and other information no smaller than 6-point.
- Minimum 0.5-point leading, letters must not touch.
- Title and headings bold italic, subheadings bold.
- Single color on a white or contrasting background.
- A horizontal barline the full width of the box between each section.
Where the panel would take more than 60 percent of available surface area, headings may drop to 7-point and leading relaxes slightly. That is a narrow accommodation, not a general license to reduce type.
Principal Display Panel and Required Statements
Separately from Drug Facts, the panels a shopper sees carry requirements under 21 CFR Part 201 Subpart C and the Fair Packaging and Labeling Act. The principal display panel must carry the statement of identity, meaning the established name of the drug and its principal intended action, plus the net quantity of contents. The name and place of business of the manufacturer, packer, or distributor must appear on the label.
The practical implication: your most valuable panel is partly spoken for before design begins.
Tamper-Evident Packaging
21 CFR 211.132 requires OTC drug products for retail sale to be packaged tamper-evident where the product is accessible to the public while held for sale. Dermatological, dentifrice, insulin, and lozenge products sit outside it.
A tamper-evident package is defined as one with indicators or barriers to entry which, if breached or missing, can reasonably be expected to give consumers visible evidence of tampering. The feature must be distinctive by design or carry an identifying characteristic that cannot readily be duplicated, and must survive manufacture, distribution, and retail display.
There is also a labeling obligation that trips people up: the package must bear a statement identifying the feature, prominently placed and positioned so it is unaffected if the feature is breached. A statement printed on a tear strip that leaves with the tear strip does not satisfy this.
For folding cartons, the common approaches are glued end flaps that show fiber tear when opened, shrink banding, and sealed cartons using a tamper-evident closure. Each has consequences for the dieline and the gluing specification, which our guide to tamper-evident packaging covers in more detail.
Child-Resistant Packaging
Child resistance comes from a different statute and agency: the Poison Prevention Packaging Act, administered by the Consumer Product Safety Commission, with substances and thresholds listed at 16 CFR 1700.14. The list covers oral aspirin, acetaminophen above 1 gram per package, ibuprofen, naproxen, diphenhydramine, elemental iron, and ethanol, which catches mouthwash.
Two things decide whether it applies to you. The threshold is the total in the package rather than per dose, so pack size alone can move a product into scope. And child resistance is a tested performance standard, not a material: the carton is rarely the resistant element, more often housing a container or blister that is. Most beauty and personal care crossovers fall outside it, but check rather than assume. Our guide to child-resistant packaging covers certification.
Lot Number, Expiration Date, and Barcodes
Section 211.137 requires expiration dating supported by stability testing, and the carton has to provide somewhere lot and expiry can be applied cleanly and read reliably: an uncoated or coating-compatible area, sized for the coder, positioned where it will not be obscured.
Barcodes are where a common assumption is wrong. FDA’s bar code rule at 21 CFR 201.25 covers prescription drugs and OTC drugs dispensed pursuant to an order and commonly used in hospitals. A retail OTC product generally falls outside it. The UPC is there because retailers require it, not because FDA does.
How OTC Packaging Differs From Prescription Packaging
The two get conflated. The differences are structural rather than a matter of stringency.
The line worth remembering: an OTC carton has to sell the product and satisfy a federal labeling scheme on the same surfaces. A prescription carton has one job. They are different design problems, not two grades of the same one. The Rx side, including DSCSA serialization, is covered in our guide to pharmaceutical packaging requirements.
Designing an OTC Carton That Is Compliant and Shelf-Ready
Four constraints do most of the work.
Panel budgeting. Lay out Drug Facts at compliant type sizes before carton dimensions are fixed. Sizing the carton from the container and the graphics, then fitting the regulatory panel afterward, is the most common and most expensive mistake in this category.
Legibility and contrast. The single-color-on-contrasting-background rule rules out choices that are routine on beauty packaging: type reversed out of a photograph, low-contrast tone-on-tone, and metallic or foil substrates behind fine type.
Fine type reproduction. 6-point type reproduces reliably only with the right substrate, screening, and register control. Smooth, bright board holds fine type better than a textured or heavily recycled surface, which is a specification decision rather than a press adjustment. It is also testable before you commit: Arkay’s Paint on Press process runs finish variations on the actual production press, so legibility and contrast on the regulatory panel can be judged on a real printed sheet rather than a proof.
Extended content. Where content genuinely will not fit, extended-content labels, peel-back panels, and outserts exist, each adding a component and a step. Treat them as a considered solution rather than a rescue.
Beyond the regulatory panel, an OTC carton is still secondary packaging doing a retail job, and the brands that win at the shelf plan the compliance panel first and design around it.
That design-around is where the premium signal lives. The Drug Facts panel constrains one face; the principal display panel and the remaining faces are unconstrained, and they can carry the same finish vocabulary as any prestige beauty carton. Foil stamping on a logo, a blind emboss or deboss on a brand mark, or an inline soft-touch aqueous coating across the display face all read as premium without touching the regulated panel. The discipline is keeping them off it: a finish that reduces contrast or disturbs fine type has no place behind Drug Facts.
Board and color. A bright, smooth, uniform board supports fine type and consistent color, and caliper is a specification decision worth making with the manufacturer rather than inheriting. Color that drifts between runs is an identification problem here, not just a shelf one, because consumers select by pack recognition. G7 color management against a physical standard is what holds it.
Change control. Monograph and labeling changes reach the carton as artwork revisions. Version control, a single named approver, and disciplined obsolescence of superseded stock prevent the failure mode where a corrected file exists but an old plate runs. Our overview of packaging quality assurance covers the controls that make this reliable.
OTC Carton Compliance Checklist
Confirm each with your regulatory function before release.
- Regulatory status confirmed: monograph, NDA or ANDA, or cosmetic-drug crossover.
- Drug Facts content complete, in the prescribed order, in a single color on a contrasting background.
- Type sizes, leading, bold treatments, and barlines verified at final artwork size.
- Statement of identity and net quantity on the principal display panel; responsible party on the label.
- Tamper-evident feature specified, with its identifying statement positioned to survive a breach.
- Child-resistance assessed against 16 CFR 1700.14 for the total quantity in the package.
- Lot and expiry coding area specified, sized, and coating-compatible.
- Retail barcode specified to the retailer’s commercial requirement.
- Artwork version controlled, single named approver, superseded stock accounted for.
- Carton specification, including board, caliper, and tolerances, agreed in writing.
Which Packaging Manufacturers Produce Compliant OTC Secondary Cartons?
A carton manufacturer cannot make your product compliant. What it can do is reproduce approved content faithfully and consistently. Judge a supplier on four things:
- Audited hygiene, traceability, and process control, evidenced by something you can inspect rather than asserted as a general quality claim.
- Documented labeling and material controls, so printed material is examined, reconciled, and traceable by run.
- Color management against a physical standard, so a reorder matches and pack recognition holds.
- Demonstrated fine-type reproduction, with inspection capable of catching a defect in 6-point type.
A high-volume program with a full labeling-control apparatus is a different brief from a premium beauty carton that happens to carry a Drug Facts panel, and it is worth being clear with a supplier about which one you are bringing.
Arkay makes premium folding cartons for cosmetics, personal care, and wellness brands, and products in those categories routinely cross into OTC labeling: the moisturizer that adds SPF, the cleanser that becomes an acne treatment, the deodorant that becomes an antiperspirant. That carton still has to hold a brand color across runs and reproduce 6-point type cleanly on a small panel, which is a printing and color problem before it is a regulatory one. Arkay is G7 color management certified and runs prepress, printing, finishing, die-cutting, and gluing under one roof in Roanoke, Virginia. It makes secondary folding cartons only, working alongside primary container suppliers rather than replacing them, and has been family-owned since 1922, now in its fourth generation.
Talk to Us Before the Panel Becomes a Problem
If you are a beauty or personal care brand whose product has crossed into OTC labeling, the carton conversation is worth having early. Tell us the product, the panel content it has to carry, and the finish you were planning, and we will work through structure, substrate, and type reproduction with you while the dimensions can still change.
Reach out to Arkay’s team with your product details and your target launch date.
For adjacent categories, our guide to health product packaging covers supplements and wellness formats where similar constraints apply.
